Intraarticular botulinum toxin compared to placebo in patients with arthritis: outcomes at 4 weeks.
| Outcome | No. Studies | No. Patients | Mean difference or Risk Ratio* (95% CI) |
|---|---|---|---|
| Pain on visual analog scale (0–10 cm; higher = worse pain) | 1 | 36 | −2.00 (−3.71, −0.29)** |
| SPADI disability subscale score (0–100; higher = worse function) | 1 | 36 | −13.40 (−24.93, −1.87)** |
| SPADI pain subscale score (0–100; higher = worse pain) | 1 | 36 | −9.10 (−20.33, 2.13) |
| Active shoulder flexion (0–180; higher = better function) | 1 | 36 | 13.80 (−9.21, 36.81) |
| Active shoulder abduction (0–180; higher = better function) | 1 | 36 | 23.60 (3.25, 43.95)** |
| McGill total pain score (0–45; higher = worse pain) | 1 | 36 | −7.20 (−13.06, −1.34) |
| McGill sensory dimension pain (0–33; higher = worse) | 1 | 36 | −4.50 (−8.96, − 0.04) |
| McGill affective dimension pain (0–12; higher = worse pain) | 1 | 36 | −2.70 (−4.39, −1.01) |
| Serious adverse events | 1 | 36 | 0.35 (0.11, 1.12) |
| No. patients with 1 or more serious adverse events | 1 | 36 | 0.79 (0.20, 3.10) |
| Death | 1 | 36 | Not estimable† |
↵* All numbers are mean differences except number of adverse events for which risk ratio is presented.
↵** Significant with p ≤ 0.02 for all. Differences are significant when 95% confidence interval for the mean difference does not include 0 and 95% confidence interval for the relative risk does not include 1. No patient in either group died. SPADI: Shoulder Pain and Disability Index.